about
Nanotechnology-mediated targeting of tumor angiogenesisReview: the Contribution of both Nature and Nurture to Carcinogenesis and Progression in Solid TumoursRecent Developments in Active Tumor Targeted Multifunctional Nanoparticles for Combination Chemotherapy in Cancer Treatment and ImagingPerspectives on reprograming cancer-associated dendritic cells for anti-tumor therapiesEnhancing integrin function by VEGF/neuropilin signaling: implications for tumor biologyNanotechnology in cancer therapyVascular permeability--the essentialsVascular normalization as a therapeutic strategy for malignant and nonmalignant disease.Vascular endothelial growth factor blockade alters magnetic resonance imaging biomarkers of vascular function and decreases barrier permeability in a rat model of lung cancer brain metastasis.Computational model of vascular endothelial growth factor spatial distribution in muscle and pro-angiogenic cell therapy.Up-regulation of intestinal vascular endothelial growth factor by Afa/Dr diffusely adhering Escherichia coliGenetic selection for peptide inhibitors of angiogenin.Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus.Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumabOutcomes and prognoses of patients with ovarian cancer using bevacizumab: 6-year experience in a tertiary care hospital of northern Taiwan.Potent inhibition of tumoral hypoxia-inducible factor 1alpha by albendazole.VEGF targets the tumour cell.Platelet-derived growth factor-B normalizes micromorphology and vessel function in vascular endothelial growth factor-A-induced squamous cell carcinomasGU81, a VEGFR2 antagonist peptoid, enhances the anti-tumor activity of doxorubicin in the murine MMTV-PyMT transgenic model of breast cancer.Enhanced specific delivery and targeting of oncolytic Sindbis viral vectors by modulating vascular leakiness in tumorRole of IL-6 in angiotensin II-induced retinal vascular inflammation.Targeted delivery of albumin bound paclitaxel in the treatment of advanced breast cancer.The interplay between surfaces and soluble factors define the immunologic and angiogenic properties of myeloid dendritic cells.Lymphangiogenesis and lymphatic metastasis in breast cancer.AAVrh.10-mediated genetic delivery of bevacizumab to the pleura to provide local anti-VEGF to suppress growth of metastatic lung tumors.A mutated soluble neuropilin-2 B domain antagonizes vascular endothelial growth factor bioactivity and inhibits tumor progressionAnti-VEGF agents for age-related macular degeneration.H-Ras regulation of TRAIL death receptor mediated apoptosisBevacizumab salvage therapy following progression in high-grade glioma patients treated with VEGF receptor tyrosine kinase inhibitors.Bioengineering strategies for designing targeted cancer therapiesCorrelation set analysis: detecting active regulators in disease populations using prior causal knowledgeInvestigation of antiangiogenic tumor therapy potential of microencapsulated HEK293 VEGF165b producing cells.Role of pancreatic stellate cells in pancreatic cancer metastasis.Vascular endothelial platelet endothelial cell adhesion molecule 1 (PECAM-1) regulates advanced metastatic progression.Rapid response to systemic bevacizumab therapy in recurrent respiratory papillomatosis.Targeting angiogenesis in advanced cervical cancer.Soy and breast cancer: focus on angiogenesis.Dynamic magnetic resonance imaging assessment of vascular targeting agent effects in rat intracerebral tumor models.Synergic antitumor effect of SKLB1002 and local hyperthermia in 4T1 and CT26.The paradoxical effect of bevacizumab in the therapy of malignant gliomas.
P2860
Q21195857-F796D947-5767-4DB3-9B1C-FFD4879039D7Q26749322-583B5FFC-5C59-401C-9C4D-DAD41D97A74FQ26778234-B0EC98C2-90BA-4C9D-8035-E1A0F2F3D47BQ26830839-43E73290-DDE4-4EF4-885A-9FCBDA840F4BQ27022814-960FC841-2830-41A6-8B82-4293A5843F43Q27023013-B2C596DD-0671-4E30-9FED-6CED91CEA100Q28085112-CE87F8F0-0B1C-4986-9BC5-5119DEFB0E6AQ30469815-769CFD26-8255-48B8-8685-BA701BDE7DABQ30934034-9C1477E7-EDB8-4454-B1E5-AF518D3305AFQ33258465-D61B998B-A5B1-49FC-8E50-FB7D1C6506ECQ33312378-FEA70F33-6C8B-4B0D-9D89-2AC83BDF62F2Q33321756-4216D82F-2920-4612-8281-C1AA22F3BCEEQ33414685-9D51C498-48DE-4A3A-B456-2C4F57D3F4BDQ33418562-7323AF66-8719-4B88-87B3-29729E46AECDQ33441574-FEB414FE-5462-489C-823B-F16CD8A21F0BQ33557565-635CC502-BE40-48DE-A6C3-D8C9D566720CQ33573324-CE1360BC-D408-4E98-A2A5-C27BE7AA6D45Q33597254-EDBCC7D5-F4A8-49B2-94ED-4550F81E64A1Q33645920-BED87A5B-FE45-4387-9C45-F2E86130B322Q33739293-3FDBA4D8-B80B-484A-83DC-139640EB962DQ33845139-79CC67E8-9F72-4938-A676-811726EC46CDQ33916040-1E71DE74-A9D9-4537-8837-ABE45421ABC8Q33924531-18C4D272-BDF5-40BC-A753-90C383A2D738Q33940058-27316CA4-B7D0-4ABC-9D66-8D73BA2412A9Q34063390-1E25E4D8-9385-462E-9416-CA88D810E6D6Q34073272-7255D2F5-EADD-4AB9-B6B5-BD7F13F8580CQ34088934-7EF7CF65-5378-4BA3-A202-F4B7CE220A7CQ34104161-2FDE0C30-C264-454A-833B-F73F163B899EQ34132928-820F547B-8D7F-4E9C-880A-D7CC82145E12Q34194191-431505D0-5F74-4DEC-80DF-D0D8E937C8CAQ34207439-D9072354-EE1D-4FC8-8C54-5661B96618F7Q34210916-82ABEE11-A027-4C5B-A611-7858063A209BQ34254595-F7BD8DE6-76DD-4876-A74A-EBC3669779DCQ34276970-1A1F9894-0218-46CB-8777-DEA17C73C0AFQ34293181-AD128ED5-F2F6-4A5C-8023-9BB940731670Q34389368-2026513B-4835-4CF8-BE67-1D445F94C898Q34477740-88A5F6AE-5451-46A7-899C-9A5C21FA978FQ34480549-74DDE852-BCDB-4443-AAD3-BACB69D818F6Q34521999-274ABFF9-B84D-4A9B-9249-140AAAF15991Q34536275-5A4BE6F3-A64A-407C-A434-723E2A7D6392
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
VEGF as a therapeutic target in cancer.
@ast
VEGF as a therapeutic target in cancer.
@en
type
label
VEGF as a therapeutic target in cancer.
@ast
VEGF as a therapeutic target in cancer.
@en
prefLabel
VEGF as a therapeutic target in cancer.
@ast
VEGF as a therapeutic target in cancer.
@en
P2860
P356
P1433
P1476
VEGF as a therapeutic target in cancer.
@en
P2093
Napoleone Ferrara
P2860
P356
10.1159/000088479
P478
69 Suppl 3
P577
2005-11-21T00:00:00Z